DaVita (DVA) has shown a significant performance in recent times despite various challenges. Over the past five years, investors who invested in DaVita (NYSE:DVA) realized a 76% return. The healthcare provider is reportedly outperforming the wider market, displaying resilience in the face of adversities, one of them being a ransomware attack that the firm successfully navigated without disruption to patient care. In addition, DaVita delivered robust earnings, beating estimates in Q1 and Q4 of 2025, despite a contraction in margins.
It is worth noting that Berkshire Hathaway, helmed by Warren Buffet, has continued to systematically sell its Davita shares, reducing its stake to 45%. Institutional sell-offs of this magnitude usually pose a concern for investors. However, despite this, DaVita is viewed positively by some experts who consider it a strong value and growth stock for long-term investments. The company has also advanced its kidney care services using AI models, further augmenting its stronghold in the healthcare sector.
Davita DVA News Analytics from Thu, 12 Sep 2024 07:00:00 GMT to Thu, 12 Jun 2025 03:34:00 GMT - Rating 2 - Innovation 4 - Information 7 - Rumor 2
